The protocol is a quintessential component of any clinical trial, and these documents are no exception to the digital revolution unfolding across the industry. Trials are shifting from traditional paper-based protocols toward digital approaches that more readily support study startup and data monitoring to provide a foundation for automation and agentic AI workflows. Digital protocols are more than a formatting upgrade; they provide a single source of truth that empowers interoperability across disparate systems.

The 2025 Industry Standard Research (ISR) report on Interactive Response Technology (IRT) benchmarking and market dynamics revealed that, for sponsors, the most important features in an IRT vendor are integration with e-clinical technologies, optimized study start up, and speed of build — qualities supported by digital protocols. Efforts to standardize digital protocols include TransCelerate BioPharma’s Digital Data Flow, whose effort is in collaboration with CDISC’s Unified Study Definitions Model (USDM) Digital Data Flow Initiative.

Recently, we got together as a group of industry experts to discuss our journey to launching digital protocols. Together, we considered what defines a digital protocol, what business problems they solve, and meaningful use cases.

What Is a Digital Protocol?

According to the ICH’s M11 Guideline, a protocol should detail the processes and methods for executing and analyzing a clinical trial.¹ Traditional protocols are delivered in a static PDF format, creating high risks for operational errors, non-compliance, inefficiency, data integrity, and safety. However, a digital protocol is a structured and machine-readable way of representing clinical trial data. It serves as a trial blueprint and provides standardized data to drive downstream operations from the outset. Furthermore, digital protocols enable the automation of study setup, scheduling, and electronic data capture (EDC).

The Digital Data Flow Initiative launched by CDISC USDM and TransCelerate Biopharma aims to provide sponsors and CROs with resources that define the key components, objectives, and endpoints related to study design and metrics for digital protocols. As a result, trial teams will have access to a ready-made workflow for capturing digital information and transforming drug development.

When looking at the sponsor journey toward the digital protocol, some organizations begin with standardized protocol templates and a roadmap to transition toward the ICH M11 format. This shift prompts sponsors to rethink how core systems, such as IRT, eCOA, eConsent, EDC, and other eSource technologies, are orchestrated and how data flows downstream. Today, much of the validation of protocol and label information still depends on manual discussions and handoffs. The promise of the digital protocol is to reduce this friction, enabling more seamless downstream integration and driving greater efficiency across the clinical technology landscape.

From the CRO perspective, the focus often begins well before digitization itself. CROs work with sponsors to analyze existing protocols, identifying inefficiencies such as unnecessary patient or site burden and assessing how protocol amendments affect study performance and cost. By taking this step upfront, CROs help ensure that only well optimized protocols move into digitization, laying the foundation for a more efficient, cost effective digital protocol implementation.

What Are the Potential Use Cases and Benefits of Digital Protocols?

Digital protocols aim to alleviate a range of challenges. First and foremost, they help organizations ensure interoperability between systems, enabling different e-clinical technologies to communicate throughout clinical operations. Plus, continuous access to digital protocol data ensures thoughtful construction of system integrations.

Digital protocols are increasingly being used as a foundation for smarter study design, deeper insight generation, and the automation of downstream clinical operations. Often described as the “heart” of a clinical trial, the digital protocol unlocks a broad range of business value when leveraged early in trial development. Sponsors are seeing quick returns by using digital protocol data to automate processes such as initiating clinical documents, enabling downstream workflows, and supporting activities like budget planning and negotiation across their clinical ecosystem.

Another advantage of the digital protocol is the establishment of a single source of truth for clinical operations, which streamlines communication and increases clarity. Protocol sections are more clearly defined, making it easier for teams to determine which protocol components an amendment will impact. As a result, teams are better prepared, transitions are smoother, and protocol amendments are less daunting.

Once a digital protocol is established, it can serve as a powerful enabler for downstream capabilities such as RTSM, digital supply chain management, master data management, and demand planning. Sponsors are increasingly exploring how advanced technologies, including AI, can be applied to validate RTSM builds against predefined rules, such as blinding requirements or third party dispensing, to reduce risk and manual oversight. At the same time, some organizations are beginning to investigate the use of digital twins, or virtual representations of physical systems, to simulate scenarios and improve supply chain resilience². Together, these innovations illustrate how the digital protocol provides a foundational layer for connecting systems, enabling automation, and supporting more intelligent, adaptive clinical trial operations across the ecosystem.

Where Does Agentic AI Fit In?

Agentic AI has moved beyond experimentation and is increasingly being operationalized across enterprise environments. MIT experts characterize these systems as capable of autonomous perception, reasoning, and action across interconnected platforms, making them well suited for complex, data-driven workflows.³ The question facing the clinical trial industry is no longer whether agentic AI belongs in clinical operations, but how it can be deployed safely, transparently, and at scale. The answer may be in disciplined implementation: structured digital inputs, clear governance models, and a human in the loop approach that balances automation with regulatory accountability.

When it comes to agentic AI frameworks and solutions, data validation is critical, especially when working with external data. Data ingestion processes must be monitored, analytics must be tracked, and data must be validated in compliance with agentic AI rules. From a broader industry perspective, agentic AI capabilities are increasingly being applied to operationalize digital protocol data at scale. These solutions can ingest data from multiple sources, assess its origin, validate it against predefined rules, continuously monitor it, and generate analytics to support reporting and decision making. Importantly, a human in the loop approach remains critical, ensuring that validated data is appropriately routed into the right systems and workflows, balancing automation with oversight to maintain trust, quality, and compliance.

Agentic AI also offers a potential implement for protocol amendment reporting, in which an agentic AI solution monitors amendments, notes changes, and extracts these changes to be uploaded to ClinicalTrials.gov to uphold continuous compliance with the FDA. Before the upload is completed, the compliance team reviews and verifies to ensure it is correct. This solution protects sponsors and promotes efficiency.

How Do Sponsors Stay Ahead of the Curve?

The future of pharma is digital. Sponsors, CROs, and other stakeholders continue to explore how digital protocols can provide the necessary prerequisites for safer AI scaling and seamless trial execution. Organizations that invest in digital protocols early gain: faster start-up, less rework, better amendment control, reduced compliance exposure, and competitive operational advantages.

References

1. ICH. (2022, October 26). ICH M11 Guideline. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m11-template-step-2b_en.pdf
2. Zaidi, S. A., Khan, S. A., & Chaabane, A. (2024). Unlocking the potential of digital twins in Supply Chains: A systematic review. Supply Chain Analytics, 7, 100075. https://doi.org/10.1016/j.sca.2024.100075
3. Stackpole, B. (2026, February 18). Agentic AI, Explained. MIT Sloan School of Management. https://mitsloan.mit.edu/ideas-made-to-matter/agentic-ai-explained